



INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP
ANNUAL MEETING - ASCONA 2005
PROGRAM

Friday February 25

8.30 – 11.30 BONE LYMPHOMA WORKING GROUP

13.30 – 14.30 *Registration at the Monte Verità, Ascona, Switzerland*

14.30 OPENING REMARKS *E. Zucca*

BRIEF INFORMATION ABOUT SOME CLOSED STUDIES *E. Zucca*

IELSG 3 - Randomized trial of observation vs chlorambucil after anti-helicobacter therapy in low-grade gastric lymphoma

IELSG 11 - Retrospective evaluation of cutaneous B-cell lymphomas

IELSG 13 - Prevalence of hepatitis C virus (HCV) infection among non-Hodgkin lymphoma (NHL) patients – feasibility study

IELSG 18 - Retrospective international survey on primary effusion lymphomas

RETROSPECTIVE STUDIES

14.45 IELSG 12 - Chromosome 11Q amplification in primary extranodal diffuse large B-cell lymphomas *F. Bertoni*

IELSG 16 - RT-PCR detection of the t(11;18) translocation as a predictor of outcome in extranodal marginal lymphoma of MALT type *F. Bertoni*

15.00 IELSG 14 - Retrospective evaluation of primary bone lymphoma *D. Christie*

15.25 IELSG 15 - Retrospective evaluation of primary breast lymphoma *G. Ryan, G. Martinelli*

15.40 IELSG 17 - Multi-institutional retrospective analysis of intravascular lymphomatosis

M. Ponzoni, A. Ferreri

15.55 IELSG 22 - Gastric irradiation for MALT lymphoma: a retrospective study *A. Wirth*

16.10 IELSG 23 - Retrospective evaluation of primary head and neck lymphoma *S. Cortelazzo*

COFFEE BREAK

ONGOING CLINICAL STUDIES

17.00 IELSG 10 - A phase II study of CHOP, with intrathecal methotrexate followed by radiotherapy, in patients with primary testicular non-Hodgkin's lymphoma *U. Vitolo*

17.15 IELSG 19 - Multicenter randomized trial of chlorambucil versus chlorambucil plus rituximab in extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT Lymphoma)

Interim analysis *I. Floriani*

CNS STUDIES

- 17.40 IELSG 20 - Randomized phase II trial on primary chemotherapy with high-dose methotrexate, alone or associated with high-dose cytarabine, followed by response- and age-tailored radiotherapy for immunocompetent patients with newly diagnosed primary central nervous system lymphoma *A. Ferreri*
 IELSG 21 - Salvage therapy with idarubicin in immunocompetent patients with relapsed or refractory primary central nervous system lymphomas *A. Ferreri*
- 17.55 International Primary Central Nervous System Lymphoma Collaborative Group (IPCG):
 1. Report of the IPCG S. Diego Meeting *A. Ferreri*
 2. Proposal of a retrospective survey of primary ocular NHL *A. Ferreri*
 3. Proposal of a survey of CNS relapses of NHL *E. Zucca*
 4. Primary central nervous system lymphoma: from an improved biology knowledge of its peculiar molecular and biologic feature towards the optimization of treatment *F. Bertoni, M. Ponzoni*

NEW PROPOSALS

- 18.30 Primary Mediastinal Lymphoma: can a IELSG study be feasible?
E. Zucca, P. Zinzani, P. Johnson
- 18.50 Phase II study of antibiotics in Primary Ocular Adnexa Lymphoma *A. Ferreri, J. Radford*
- 19.10 A retrospective study of primary pancreatic NHL *A. Arcari*
- 19.20 The LLMPP (Lymphoma/Leukemia Molecular Profiling Project) proposal *F. Cavalli*

20.00 *DINNER*

Saturday February 26

7.30 BOARD OF DIRECTORS BREAKFAST MEETING

9.00 **EDUCATIONAL LECTURE**
WHO/EORTC consensus classification for cutaneous lymphomas
G. Burg, Zürich, Switzerland

COFFEE BREAK

PRESENTATION OF NEW CLINICAL STUDIES

- 10.15 New treatment modality with 2-CdA/Rituximab in Lymphoplasmacytoid Lymphoma
G. Martinelli
- 10.25 IELSG 24 - A Phase I Study of Intrathecal Rituximab in Patients with Lymphomatous Meningitis *A. Conconi*
 IELSG 25 - Phase II Study of VELCADE™ in patients with extranodal marginal zone B-cell lymphoma of MALT-type pretreated with prior systemic therapy regimen *A. Conconi*
- 10.45 IELSG PLENARY GENERAL ASSEMBLY
 Discussion of the rules for IELSG membership
- 12.00 CLOSING REMARKS *F. Cavalli*